ArticleParasites & vectors2026
The American Heartworm Society and Association of Shelter Veterinarians' 2024 Shelter Heartworm Management Practices Survey.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retrospective review of clinical and anesthetic findings in 164 heartworm-positive dogs undergoing spay-neuter surgery.Parasites & vectors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2024 Shelter Heartworm Management Practices Survey was performed to update current knowledge on heartworm management practices in animal shelters, including prevention, diagnosis, and treatment.
methodsThe survey mirrored the 2019 survey with updates to questions based on new products and practices. The electronic survey was then distributed to veterinarians working with animal shelters in North America.
resultsA total of 135 responses were received and distributed across private humane societies, municipal shelters, traditional shelters, breed/species-specific rescues, and foster-based organizations. Most organizations (77%) provided monthly heartworm preventives for dogs, using oral ivermectin products per label (50%), followed by oral milbemycin (33%). Shelters in the Midwest provided the highest percentage of heartworm preventives to both dogs and cats (37% and 40%), followed by the Southeast (31% and 34%). Heartworm testing was conducted in 76.2% of shelters for all dogs > 6 months of age, primarily using antigen testing (96.4%). Heartworm treatment was provided to all infected dogs in 66.1% of shelters. Those that only treated some dogs (22.9%) made treatment decisions based on adoptability (48.1%) and resources (25.9%). Primary adulticidal treatment was a three-dose melarsomine protocol (70.5%), followed by a two-dose melarsomine protocol (22.9%). A majority included doxycycline or minocycline and other common adjunctive treatments included steroids (75.3%) and macrocyclic lactones (60.2%). Heartworm-positive dogs were typically housed in the shelter (67%) or foster homes (49.5%) and made available for adoption. Exercise restrictions were applied in 80.6% of shelters, starting at diagnosis (55.8%) and continuing for several weeks after the last melarsomine injection (89.6%). During the restriction period, 58.2% of the shelters used psychopharmaceutical medications. Heartworm prevention was provided by 49.1% of shelters who admitted cats and 25.9% of those who admitted ferrets. Compared to 2019, shelter respondents reported increased use of preventives, microfilaria testing, doxycycline and three-dose melarsomine treatment for dogs, and a decrease in use of protocols for prevention of feline heartworm disease.
conclusionsSurvey results highlight the challenges shelters have faced and the improvements made over the past 5 years, offering insights for targeted operational and educational improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.